Quanterix Presented Ultrasensitive Technology at NFL Health and Safety Update & Interactive Head Health Showcase
February 5, 2016
Quanterix announces that is participating in the NFL Health and Safety Update & Interactive Head Health Showcase at Super Bowl 50.
Frontage Laboratories Announces Partnership with Quanterix and Validation of Simoa HD-1 Analyzer and Software to Support Biomarker Analysis
June 15, 2016
Frontage Laboratories, Inc., a Contract Research Organization based in Pennsylvania, New Jersey and China, announces that they are the first CRO to complete a GLP validation of the Simoa HD-1 Analyzer and software along with the interface to Watson LIMS.
January 9. 2017
Amended licensing agreement with long-term partner allows Quanterix to continue innovation and commercialization within its expanding fields
Quanterix’ CEO to Host Webinar on the Importance of Biomarkers for the Transformation of Precision Health
June 22, 2017
CEO and Chairman, Kevin Hrusovsky, will be hosting a webinar on the use of ultrasensitive biomarker assays to enable precision health, with a specialty focus on concussion and traumatic brain injury (TBI) detection and diagnostics. Hrusovsky will be joined by Dr. Jessica Gill, Investigator at…
Business Wire| November 27, 2017
Quanterix Corporation today announced the commencement of the initial public offering of shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “Commission”).
Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer
CAMBRIDGE, MA – May 23, 2010 – Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company’s proprietary technology that demonstrates an unprecedented sensitivity…
Quanterix and Sony DADC to Develop and Manufacture Smart Consumables for Life Science and In Vitro Diagnostic Applications
CAMBRIDGE, MA and SALZBURG, Austria – July 20, 2011 – Quanterix Corporation, enabling a new generation of diagnostic tests based on the revolutionary Single Molecule Array (SiMoA™) technology, and Sony DADC Austria AG, today announced that they have entered into a collaboration for the development…
Quanterix Develops Microfluidic Consumable That Will Enable Next Generation Molecular Diagnostic Systems Based on Single Molecule Array Technology
CAMBRIDGE, MA – December 22, 2011 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, has reported a method for detecting individual proteins within microfabricated polymer arrays produced…
Quanterix’s Ultrasensitive Simoa™ Technology Forges New Ground with Direct Detection of Genomic DNA in Human Blood and River Water
LEXINGTON, Mass., January 22, 2013 – Quanterix Corporation announced today that Analytical Chemistry has published a ground-breaking study in which its Simoa technology was used to directly measure bacterial genomic DNA of S. aureus in both human blood and river water at sub-femtomolar…
Lexington, Mass. – February 20, 2014 – Quanterix Corporation, Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that it was one of the 33 recipients of the Massachusetts Life…